BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35530653)

  • 1. Circulating Cell-free DNA in Serum as a Marker for the Early Detection of Tumor Recurrence in Breast Cancer Patients.
    Bera A; Russ E; Karaian J; Landa A; Radhakrishnan S; Subramanian M; Hueman M; Pollard HB; Hu H; Shriver CD; Srivastava M
    Cancer Diagn Progn; 2022; 2(3):285-292. PubMed ID: 35530653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative analysis of serum cell-free DNA as a predictive and prognostic marker in breast cancer patients.
    Sultana GNN; Akter F; Israfil SMH; Ray UC; Jahan RA; Ali MS; Din SA; Rahman S; Halim R; Alam MS
    Front Oncol; 2023; 13():1171412. PubMed ID: 37427131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of cell-free DNA (cfDNA) concentrations in the perioperative period can predict risk of recurrence in patients with non-metastatic breast cancer.
    Hassan F; Wang JH; Cullinane C; Ita M; Corrigan M; O'Leary DP; Redmond HP
    Surg Oncol; 2022 Jun; 42():101753. PubMed ID: 35594723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma cell-free DNA chromosomal instability analysis by low-pass whole-genome sequencing to monitor breast cancer relapse.
    Zhou H; Wang XJ; Jiang X; Qian Z; Chen T; Hu Y; Chen ZH; Gao Y; Wang R; Ye WW; Cao WM
    Breast Cancer Res Treat; 2019 Nov; 178(1):63-73. PubMed ID: 31364001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new approach to epigenome-wide discovery of non-invasive methylation biomarkers for colorectal cancer screening in circulating cell-free DNA using pooled samples.
    Gallardo-Gómez M; Moran S; Páez de la Cadena M; Martínez-Zorzano VS; Rodríguez-Berrocal FJ; Rodríguez-Girondo M; Esteller M; Cubiella J; Bujanda L; Castells A; Balaguer F; Jover R; De Chiara L
    Clin Epigenetics; 2018; 10():53. PubMed ID: 29686738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis.
    Madhavan D; Wallwiener M; Bents K; Zucknick M; Nees J; Schott S; Cuk K; Riethdorf S; Trumpp A; Pantel K; Sohn C; Schneeweiss A; Surowy H; Burwinkel B
    Breast Cancer Res Treat; 2014 Jul; 146(1):163-74. PubMed ID: 24838941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High mutation burden of circulating cell-free DNA in early-stage breast cancer patients is associated with a poor relapse-free survival.
    Kujala J; Hartikainen JM; Tengström M; Sironen R; Kosma VM; Mannermaa A
    Cancer Med; 2020 Aug; 9(16):5922-5931. PubMed ID: 32602248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic significance assessment of the circulating cell-free DNA in ovarian cancer: An updated meta-analysis.
    Li B; Pu K; Ge L; Wu X
    Gene; 2019 Sep; 714():143993. PubMed ID: 31330238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating cell-free DNA: a promising marker of regional lymphonode metastasis in breast cancer patients.
    Agostini M; Enzo MV; Bedin C; Belardinelli V; Goldin E; Del Bianco P; Maschietto E; D'Angelo E; Izzi L; Saccani A; Zavagno G; Nitti D
    Cancer Biomark; 2012; 11(2-3):89-98. PubMed ID: 23011155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Spindler KG; Boysen AK; Pallisgård N; Johansen JS; Tabernero J; Sørensen MM; Jensen BV; Hansen TF; Sefrioui D; Andersen RF; Brandslund I; Jakobsen A
    Oncologist; 2017 Sep; 22(9):1049-1055. PubMed ID: 28778958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Inao T; Sueta A; Fujiwara S; Omoto Y; Iwase H
    Oncotarget; 2016 May; 7(22):32504-18. PubMed ID: 27102299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer.
    Schou JV; Larsen FO; Sørensen BS; Abrantes R; Boysen AK; Johansen JS; Jensen BV; Nielsen DL; Spindler KL
    Ann Oncol; 2018 Mar; 29(3):610-615. PubMed ID: 29253083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating cell-free DNA (cfDNA) levels in BRCA1 and BRCA2 mutation carriers: A preliminary study.
    Douvdevani A; Bernstein-Molho R; Asraf K; Doolman R; Laitman Y; Friedman E
    Cancer Biomark; 2020; 28(3):269-273. PubMed ID: 32280079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-Related Methylated Cell-Free DNA and Circulating Tumor Cells in Melanoma.
    Salvianti F; Orlando C; Massi D; De Giorgi V; Grazzini M; Pazzagli M; Pinzani P
    Front Mol Biosci; 2015; 2():76. PubMed ID: 26779490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic value of circulating cell-free DNA in breast cancer: A meta-analysis.
    Tan G; Chu C; Gui X; Li J; Chen Q
    Medicine (Baltimore); 2018 Mar; 97(13):e0197. PubMed ID: 29595655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer.
    Balgkouranidou I; Chimonidou M; Milaki G; Tsarouxa EG; Kakolyris S; Welch DR; Georgoulias V; Lianidou ES
    Br J Cancer; 2014 Apr; 110(8):2054-62. PubMed ID: 24642624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer.
    Uehiro N; Sato F; Pu F; Tanaka S; Kawashima M; Kawaguchi K; Sugimoto M; Saji S; Toi M
    Breast Cancer Res; 2016 Dec; 18(1):129. PubMed ID: 27993161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accuracy of analysis of cfDNA for detection of single nucleotide variants and copy number variants in breast cancer.
    Yang X; Zhang K; Zhang C; Peng R; Sun C
    BMC Cancer; 2019 May; 19(1):465. PubMed ID: 31101027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of postoperative circulating cell-free DNA in operable hepatocellular carcinoma.
    Long G; Fang T; Su W; Mi X; Zhou L
    Scand J Gastroenterol; 2020 Dec; 55(12):1441-1446. PubMed ID: 33119422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A quantitative analysis of the potential biomarkers of non-small cell lung cancer by circulating cell-free DNA.
    Wei L; Wu W; Han L; Yu W; Du Y
    Oncol Lett; 2018 Oct; 16(4):4353-4360. PubMed ID: 30250538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.